SCHEMBL1025318

SCHEMBL1025318

CN(C)C(=O)N1CCC1

nearest known ligand 0.00

⚠ Novel chemotype — no close known analogue (best Tanimoto < 0.3). Unexplored chemical space relative to ChEMBL.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL880638 0.94 MAPT (0.54)
SCHEMBL378130 0.92 MAPT (0.52)
SCHEMBL11035687 0.92 MAPT (0.52)
SCHEMBL25821277 0.89 HTT (0.48)
SCHEMBL282864 0.88
SCHEMBL13902804 0.87 HTR1A (0.52)
SCHEMBL23384238 0.83 CHRNA7 (0.46)
SCHEMBL27324559 0.82 KMT2A (0.43)
SCHEMBL2919261 0.82 MAPT (0.44)
SCHEMBL2919264 0.80 CA2 (0.50)

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 73 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
CN-115835908-A Bicyclic heterocycles as FGFR inhibitors 因赛特公司 2023-03-21 CN claimed
CN-108473464-B Isoindolinone inhibitors of MDM2-P53 interaction with anti-cancer activity 阿斯泰克斯治疗有限公司 2022-08-23 CN claimed
CN-111343986-A Compounds and pharmaceutical compositions thereof for the treatment of fibrotic diseases 加拉帕戈斯股份有限公司 2020-06-26 CN claimed
CN-108473464-A The isoindoline ketone inhibitors of MDM2-P53 interactions with active anticancer 阿斯泰克斯治疗有限公司 2018-08-31 CN claimed
CN-103797011-B As compound and the composition of c-Kit kinase inhibitor NOVARTIS AG (CH) 2016-03-30 CN claimed
CN-105120871-A Use of pyrazolopyrimidine derivatives for the treatment of PI 3K-related disorders INCYTE CORP 2015-12-02 CN claimed
CN-103270036-B As antiparasitic isoxazoline derivative ZOETIS LLC (US) 2015-11-25 CN claimed
CN-103159742-B 5-chloropyrimide compounds and the application as EGFR tyrosine kinase inhibitor thereof BEIJING HANMEI PHARMACEUTICAL CO., LTD. (CN) 2015-08-12 CN claimed
CN-104024253-A Heterocyclic amines as PI3K inhibitors INCYTE CORP 2014-09-03 CN claimed
CN-103270036-A Isoxazoline derivatives as antiparasitic agents PFIZER 2013-08-28 CN claimed
CN-103159742-A 5-Chloropyrimidine compound and application of 5-Chloropyrimidine compound serving as epidermal growth factor receptor (EGFR) tyrosine kinase inhibitor BEIJING HANMEI PHARMACEUTICAL CO LTD 2013-06-19 CN claimed
WO-2010049731-A1 PYRAZOLO- AND IMIDAZOPYRIDINYLPYRIMIDINEAMINES AS IGF-1R TYROSINE KINASE INHIBITORS ASTRAZENECA AB (SE) 2010-05-06 WO claimed
US-6992115-B2 Preparation of crosslinked particles from polymers having activatible crosslinking groups INTERNATIONAL BUSINESS MACHINES CORPORATION (US) 2006-01-31 US claimed
US-20050202338-A1 PREPARATION OF CROSSLINKED PARTICLES FROM POLYMERS HAVING ACTIVATIBLE CROSSLINKING GROUPS HAWKER CRAIG J (US) 2005-09-15 US claimed
US-20030168251-A1 Preparation of crosslinked particles from polymers having activatible crosslinking groups INTERNATIONAL BUSINESS MACHINES CORPORATION 2003-09-11 US claimed
EP-4288426-B1 QUINOXALINE DERIVATIVES AND USES THEREOF BLACK DIAMOND THERAPEUTICS INC (US) 2026-02-04 EP disclosed
EP-4630410-A1 POLQ INHIBITORS Astrazeneca AB (SE) 2025-10-15 EP disclosed
US-20050202338-A1 PREPARATION OF CROSSLINKED PARTICLES FROM POLYMERS HAVING ACTIVATIBLE CROSSLINKING GROUPS HAWKER CRAIG J (US) 2005-09-15 US disclosed
US-6890703-B2 Preparation of crosslinked particles from polymers having activatible crosslinking groups INTERNATIONAL BUSINESS MACHINES CORPORATION (US) 2005-05-10 US disclosed
US-20030168251-A1 Preparation of crosslinked particles from polymers having activatible crosslinking groups INTERNATIONAL BUSINESS MACHINES CORPORATION 2003-09-11 US disclosed